C-Path device director
This article was originally published in The Gray Sheet
Executive Summary
Ellen Feigal, MD, has been appointed director of medical devices and imaging of the Critical Path Institute (C-Path) in Tucson, Ariz., announced April 24. C-Path is a partner to FDA's Critical Path initiative to speed drugs, devices and diagnostics to market (1"The Gray Sheet" March 27, 2006, p. 5). Feigal worked at the National Cancer Institute from 1992 to 2004, where she spent her last three years as director of the Division of Cancer Treatment and Diagnostics. Currently, she is on sabbatical from the personalized medicine-focused Translational Genomics Research Institute (TGen), where she is VP-clinical sciences and deputy scientific director. Additionally, Jeffrey Cossman, MD, was appointed as C-Path's chief scientific officer April 18. Cosson has served as a senior scientist at the National Cancer Institute and the National Institutes of Health, and most recently was VP and medical director at genomics company Gene Logic...
You may also be interested in...
C-Path Institute Exec Targets “Points Of Pain” In Device Development
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products
Imaging Is Key To Product Development In Critical Path Opportunities List
Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.